Condition: Complication of Renal Dialysis · End Stage Renal Disease · End Stage Kidney Disease · Sponsor: Vascular Therapies, Inc.
The primary study objective is to evaluate the benefit of the Sirolimus eluting Collagen implant (SeCI; Sirogen), a single dose prophylactic treatment delivered intraoperatively at the time of surgical creation of an arteriovenous fistula for hemodialysis vascular access.
This description comes directly from the study's public registry record.
Contact details are listed per location below or on the registry record.
Always discuss trial participation with your own doctor first.
| Veterans Affairs San Diego Health Center | San Diego, California, United States | — |
| Lundquist Institute for Biomedical Innovation | Torrance, California, United States | — |
| MedStar Cardiovascular Research Network at MedStar Washington Hospital Center | Washington D.C., District of Columbia, United States | — |
| American Access Care of Miami | Miami, Florida, United States | — |
| Emory University Hospital Midtown | Atlanta, Georgia, United States | — |
| Augusta University | Augusta, Georgia, United States | — |
| University of Louisville | Louisville, Kentucky, United States | — |
| The Brigham and Women's Hospital | Boston, Massachusetts, United States | — |
| Mount Sinai Hospital | New York, New York, United States | — |
| Atrium Health | Charlotte, North Carolina, United States | — |
| Surgical Specialists of Charlotte | Charlotte, North Carolina, United States | — |
| The Regional Medical Center/Dialysis Access Institute | Orangeburg, South Carolina, United States | — |
+ 10 more locations — full list on the registry record.
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT05425056